Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH, a smart dose-controlled medical device. It also has patents pending on its telemedicine station, MDZone. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.
Vivera is committed to the continued research and development of innovative therapies across the spectrum. We believe that now is the time to combat some of the most unprecedented issues affecting patients and their caregivers by redefining the landscape with safe, yet effective, non-addictive treatment alternatives for pain management and the latest in medical device technologies. From strength in vision to channeled realization, we believe the path forward begins with the requirement to put patients first. Our foremost mission is to enhance the lives of millions of neighbors, families, and the leaders of tomorrow, through ceaseless development of life-changing new therapies.
Vivera is dedicated to making a positive difference for vulnerable communities across the world. Through our non-profit organization, Vivera Cares, we are helping underserved communities, like Tribal Nations and frontline workers, access the resources they need to keep their communities safe and healthy. With our continued support, we can envision a brighter future for our communities, patients, and providers.
Last month, Vivera was proud to support local, state, and federal law enforcement agencies and firefighters for a complex, coordinated terrorist attack exercise. The Company
NEWPORT BEACH, Calif.— Vivera extends an invitation to AbbVie’s Allergan to partner on its high-tech medical device, ZICOH, designed to end addiction, in light of
NEWPORT BEACH, Calif—Amid government settlement discussions with Teva Pharmaceuticals regarding its potential role in the opioid crisis, Vivera invites Teva to join as a partner
NEWPORT BEACH, Calif. — Vivera is pleased to announce the appointment of Guido Jouret, Ph.D., to the Company’s Board of Advisors as Senior Technology Advisor and
NEWPORT BEACH, Calif. — Vivera is pleased to welcome two Advisors to the Company’s Technology Advisory Board, Mr. Robert Massoudi and Mr. Bryan Hughes. Mr.
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals is pleased to welcome Fabio Macciardi, M.D., Ph.D., to its Advisory Board as Neurogenetics Scientific Advisor to the Company’s Biosciences Division.
Last year, our country hit a grim milestone. Overdose deaths surpassed 100,000 for the first time in a 12-month period. More than 64,000 of these
Telemedicine involves the use of electronic communications and software like computers, video, phones, or messaging to provide clinical services to patients virtually. Telemedicine can effectively
Poisoning can happen to people of all ages, but incidences disproportionately affect children younger than six years old, with peak poison frequency occurring in one and two-year-olds.
Opioids are medications prescribed by doctors to treat pain. They are called opioids because they attach to the opioid receptors in the brain and throughout
The United States has been fighting an opioid epidemic since the late 1990s. Unfortunately, much of our progress has backtracked during the COVID-19 pandemic. Not
Opioids are a drug class used to reduce pain. They work by binding to opioid receptors throughout the body to block pain messages sent to the brain
Innovation is the lifeblood of Vivera. With six divisions, each focused on a specific crisis response, Vivera’s vertically integrated structure has created an agile and responsive model.
Vivera is working to change the future of drug delivery, medical device, and medical technologies at home and across the globe with its extensive intellectual property portfolio.
English
Arabic
Armenian
Chinese (Simplified)
Chinese (Traditional)
Czech
Dutch
Tagalog
French
Frisian
German
Irish
Italian
Korean
Farsi
Polish
Portuguese
Romanian
Russian
Spanish
Swedish
Ukrainian
Vietnamese